Compare CING & CRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CING | CRGO |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 66.7M |
| IPO Year | 2021 | 2022 |
| Metric | CING | CRGO |
|---|---|---|
| Price | $5.21 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $34.50 | $2.40 |
| AVG Volume (30 Days) | 133.6K | ★ 246.3K |
| Earning Date | 05-08-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.61 |
| Revenue Next Year | N/A | $16.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $1.14 |
| 52 Week High | $11.89 | $4.24 |
| Indicator | CING | CRGO |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 41.69 |
| Support Level | $5.08 | $1.17 |
| Resistance Level | $5.54 | $1.43 |
| Average True Range (ATR) | 0.31 | 0.09 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 27.17 | 3.45 |
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters, thousands of forwarders, and dozens of airlines and ocean carriers. The company operates in two segments: the Platform segment and the Solutions segment. The majority of the revenue is derived from the Solutions segment, which provides software tools and data to help industry participants automate their pricing, sales, and procurement processes. Geographically, it generates the maximum revenue from Europe, and the rest from the United States, Hong Kong and Others.